Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
RESEARCH TOOLSreports
DNLI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.56 - $33.33
Previous CloseN/A
Volume399.31K
Average Volume (3M)929.49K
Market Cap
$2.98B
Enterprise Value$4.15B
Total Cash (Recent Filing)$77.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Mar 03, 2025EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.76
Shares Outstanding143,921,630
10 Day Avg. Volume796,564
30 Day Avg. Volume929,489
Standard Deviation0.17
R-Squared0.18
Alpha-0.00211
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.03
Price to Cash Flow (P/CF)-12.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.23
Enterprise Value/Ebitda-8.37
Forecast
1Y Price Target
$38.42Price Target Upside132.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityDenali guides to a runway into 2028 based on ~$1.3B in cash/equivalent as of 3Q24, providing financial stability for future developments.
Regulatory ProgressTivi was previously granted breakthrough therapy designation, increasing confidence in a priority review and enabling launch by late 2025 or early 2026.
Bears Say
Clinical Trial ResultsThe 24-week co-primary endpoints of slowing disease progression, i.e., ALS Functional Rating Scale-Revised (ALSFRS-R) and survival, were not met.
---
Ownership Overview
9.16% Insiders
33.39% Mutual Funds
30.59% Other Institutional Investors
11.41% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $14.56 and its highest was $33.33 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $2.98B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Mar 03, 2025 which is tomorrow.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.67 earnings per share for the quarter, beating the consensus estimate of -$0.799 by $0.129.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.8.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 143,921,630 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.67 in its last earnings report, beating expectations of -$0.799. Following the earnings report the stock price went down -10.968%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DNLI
---
Denali Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.42 (132.00% Upside)
$38.42 (132.00% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 354.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.06%
12-Months-Change
Fundamentals
Return on Equity
-37.40%
Trailing 12-Months
Asset Growth
19.09%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
---
DNLI Stock 12 Month Forecast
Average Price Target
$38.42
▲(132.00% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Biogen
―
Neurocrine
―
Vertex Pharmaceuticals
―
PTC Therapeutics
―
Best Analysts Covering DNLI
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+29.93%
reiterated a buy rating last month
Copying Salveen Richter's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +29.93% per trade.
---